Trevi Therapeutics financials
$14.42+0.14%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 |
|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | — | — | — |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | — | — | — |
| Gross margin | — | — | — | — | — | — | — |
| Operating income | -$49.3M | -$51.5M | -$33.9M | -$29.9M | -$32.5M | -$32.5M | -$26.6M |
| Net income | -$42.8M | -$47.9M | -$29.1M | -$29.2M | -$33.9M | -$32.8M | -$26.8M |
| Net margin | — | — | — | — | — | — | — |
| Diluted EPS | $-0.32 | $-0.47 | $-0.29 | $-0.45 | $-1.49 | $-1.81 | $-2.28 |
| EBITDA | -$49.2M | -$51.4M | -$33.8M | -$29.9M | -$32.4M | -$32.4M | -$26.6M |
| Operating cash flow | -$42.1M | -$38.3M | -$31.7M | -$28.2M | -$28.9M | -$29.0M | -$23.1M |
| Free cash flow | -$42.1M | -$38.3M | -$31.8M | -$28.3M | — | -$29.0M | -$23.1M |
| Diluted shares | 134.7M | 102.0M | 99.0M | 64.5M | 22.8M | 18.1M | 11.7M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $18.9M | $34.1M | $32.4M | $12.6M | $36.8M | $45.0M |
| Short-term investments | $169.3M | $73.5M | $50.6M | $107.9M | — | — |
| Total debt | $0.00 | $31.0K | $153.0K | $9.2M | $14.5M | $14.0M |
| Total assets | $193.4M | $110.9M | $89.4M | $123.0M | $38.5M | $47.1M |
| Total liabilities | $10.2M | $11.3M | $6.9M | $15.6M | $21.4M | $19.8M |
| Shareholders' equity | $183.2M | $99.6M | $82.5M | $107.5M | $17.1M | $27.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology